# Agent 8 Benchmark Report - 34_multi_turn

**Generated:** 2026-06-03 21:29:17
**Agent:** 8
**Category:** 34_multi_turn

## Executive Summary

| Metric | Value |
|--------|-------|
| Total Tests | 7 |
| Passed | 4 |
| Failed | 3 |
| Pass Rate | 57.1% |
| Avg Score | 0.840 |

### Failure Root Causes

| Root Cause | Count | % of Failures | Severity |
|------------|-------|---------------|----------|
| language_mismatch | 1 | 33.3% | P1 |
| too_brief | 1 | 33.3% | P2 |

## Detailed Results

### ✅ MT001

**Multi-turn Test:** 2 turns

#### Turn 1 ✅

**Input:** What is the prescription dose for I-125 prostate brachytherapy?...

**Response:**
> [Historical reference — not current task]I-125 Prostate Brachytherapy Prescription Dose:ProtocolDoseMonotherapy144 GyBoost with EBRT108-110 Gy (plus ~45 Gy EBRT)Reference: AAPM TG-64, ABS (American Brachytherapy Society) guidelinesThe 144 Gy monotherapy dose assumes a minimal peripheral dose (MPD) to the prostate gland with standard loading patterns. Dose may be adjusted based on prostate volume, patient anatomy, and institutional protocols....

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 1](../screenshots/34_MT001_turn1.png)

---

#### Turn 2 ✅

**Input:** And what about for Pd-103?...

**Response:**
> [Historical reference — not current task]**Pd-103 Prostate Brachytherapy Prescription Dose:**| Protocol | Dose ||----------|------|| **Monotherapy** | **125 Gy** || **Boost with EBRT** | **90-100 Gy** (plus ~45 Gy EBRT) |**Reference**: AAPM TG-64, ABS guidelines**Key Difference from I-125:**| Isotope | Half-life | Photon Energy | Typical Monotherapy Dose ||---------|-----------|---------------|-------------------------|| I-125 | 59.4 days | 28 keV | 144 Gy || Pd-103 | 17 days | 21 keV | 125 Gy |Pd-103's shorter half-life provides faster dose delivery, which may be advantageous for higher grade tumors (Gleason...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 2](../screenshots/34_MT001_turn2.png)

---

### ✅ MT002

**Multi-turn Test:** 3 turns

#### Turn 1 ✅

**Input:** What V100 should I aim for in prostate brachytherapy?...

**Response:**
> [Historical reference — not current task]Prostate Brachytherapy V100 Target:MetricTargetV100≥ 95% (ideally 95-99%)ABS Guidelines:Minimum: 90% (absolute floor)Optimal: 95-99%Values >99% may indicate excessive seeds or hot spotsOther Key Coverage Metrics:ParameterTargetD90 (dose to 90% of prostate)≥ 100% of prescriptionV15030-50% (acceptable range)V20010-20% (acceptable range)Note: V100 alone is insufficient — D90, OAR doses, and dose homogeneity (DHI > 0.25) must also be evaluated for plan quality.Source: ABS "Consensus Statement on Plasma Sampling for Prostate Brachytherapy" and TG-43 recommendations....

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 1](../screenshots/34_MT002_turn1.png)

---

#### Turn 2 ✅

**Input:** My plan has V100=93%, is that acceptable?...

**Response:**
> [Historical reference — not current task]**V100 = 93% is marginal — not ideal, but may be acceptable with caveats.**| Assessment | Value ||------------|-------|| ABS Minimum | ≥ 90% ✓ (passes) || ABS Optimal | 95...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 2](../screenshots/34_MT002_turn2.png)

---

#### Turn 3 ✅

**Input:** What can I do to improve it?...

**Response:**
> [Historical reference — not current task]**V100 = 93% is marginal — not ideal, but may be acceptable with caveats.**| Assessment | Value ||------------|-------|| ABS Minimum | ≥ 90% ✓ (passes) || ABS Optimal | 95-99% ✗ (below target) |**Considerations:**1. **If D90 ≥ 100%**: The 93% V100 may still deliver adequate dose to the prostate, as D90 is often a better predictor of outcome2. **Cold spots**: Evaluate location — small peripheral cold spots are higher risk than central ones3. **Prostate motion/uncertainty**: 93% on planning CT may drop further accounting for intraoperative changes**Recommendation:**- Investigate whether coverage can be improved without increasing...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 3](../screenshots/34_MT002_turn3.png)

---

### ✅ MT003

**Multi-turn Test:** 2 turns

#### Turn 1 ✅

**Input:** What is the rectal dose constraint for prostate brachytherapy?...

**Response:**
> [Historical reference — not current task][Historical reference — not current task]**V100 = 93%: Borderline Acceptable**- **Minimum** per ABS: 90% ✓ (you meet this)- **Optimal**: 95-99% ✗ (below optimal)- **93% is acceptable but suboptimal** — consider if you can improve coverage without violating OAR constraints.---**Rectal Dose Constraints for Prostate Brachytherapy:**| Constraint | Limit | Priority ||------------|-------|----------|| **Rectal D2cc** | ≤ 100% of prescription dose (~144 Gy for I-125) | Critical || **Rectal V100** | < 1.0-1.3 cc | Important || **Rectal V150** | < 0.1-0.3 cc | Important || **Rectal V200** | < 0.1 cc | Important...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 1](../screenshots/34_MT003_turn1.png)

---

#### Turn 2 ✅

**Input:** My plan has D2cc=75 Gy for the rectum. Is that safe?...

**Response:**
> [Historical reference — not current task][Historical reference — not current task]**V100 = 93%: Borderline Acceptable**- **Minimum** per ABS: 90% ✓ (you meet this)- **Optimal**: 95-99% ✗ (below optimal)- **93% is acceptable but suboptimal** — consider if you can improve coverage without violating OAR constraints.---**Rectal Dose Constraints for Prostate Brachytherapy:**| Constraint | Limit | Priority ||------------|-------|----------|| **Rectal D2cc** | ≤ 100% of prescription dose (~144 Gy for I-125) | Critical || **Rectal V100** | < 1.0-1.3 cc | Important || **Rectal V150** | < 0.1-0.3 cc | Important || **Rectal V200** | < 0.1 cc | Important |**Practical Thresholds (I-125 144 Gy):**- D2cc ≤ 130-140 Gy (some institutions use stricter limits)- No more than 1 cc of rectum receiving prescription dose**Sources**: QUANTEC, ABS Guidelines, AAPM TG-64⚠️ **If V100=93% but OARs are all within constraints...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 2](../screenshots/34_MT003_turn2.png)

---

### ✅ MT004

**Multi-turn Test:** 2 turns

#### Turn 1 ✅

**Input:** 前列腺癌的处方剂量是多少？...

**Response:**
> [Historical reference — not current task]前列腺癌近距离放疗处方剂量：治疗方式同位素处方剂量单药治疗I-125144 Gy单药治疗Pd-103125 Gy单药治疗Cs-131115 Gy联合EBRT增强I-125108-110 Gy + 45 Gy EBRT联合EBRT增强Pd-10390-100 Gy + 45 Gy EBRT参考标准：AAPM TG-64ABS（美国近距离治疗学会）指南中国前列腺癌诊疗指南关键剂量参数：D90 ≥ 处方剂量的 100%V100 ≥ 95%（理想值）直肠 D2cc ≤ 处方剂量的 65-75%（约 72-100 Gy 等效剂量）如需更具体的剂量计算或计划评估，请上传 CT 图像。...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 1](../screenshots/34_MT004_turn1.png)

---

#### Turn 2 ✅

**Input:** 那V100目标呢？...

**Response:**
> [Historical reference — not current task]**前列腺近距离放疗 V100 目标：**| 指标 | 目标值 ||------|--------|| **V100** | **≥ 95%**（理想范围 95-99%） || 最低限制 | ≥ 90%（绝对底线） |**注意**：V100 需结合其他指标综合...

**Scores:**
- Total: 1.00
- Keyword: 1.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 2](../screenshots/34_MT004_turn2.png)

---

### ❌ MT005

**Multi-turn Test:** 2 turns

#### Turn 1 ❌

**Input:** What is the prescription dose for I-125 prostate brachytherapy?...

**Response:**
> I-125 前列腺癌近距离放疗处方剂量：治疗方案剂量单药治疗（Monotherapy）144 Gy联合EBRT增强（Boost）108-110 Gy（+ 约45 Gy外照射）参考依据：AAPM TG-64、ABS（美国近距离治疗学会）指南说明：144 Gy 适用于单纯近距离放疗（低风险前列腺癌）联合治疗时剂量降低，因为外照射会补充部分剂量处方剂量基于前列腺边缘最低剂量（MPD）计算...

**Scores:**
- Total: 0.77
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Turn 1](../screenshots/34_MT005_turn1.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

#### Turn 2 ✅

**Input:** What about the 5-year survival rate at Memorial Hospital?...

**Response:**
> I don't have access to specific institutional data like survival rates for Memorial Hospital. This information is typically:1. **Published in hospital annual...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 2](../screenshots/34_MT005_turn2.png)

---

### ❌ MT006

**Multi-turn Test:** 2 turns

#### Turn 1 ❌

**Input:** What is V100?...

**Response:**
> V100 是放射治疗计划中的剂量体积参数，定义为：接受≥100%处方剂量的靶区体积百分比。计算公式：📋V100 (%) = (接受≥100%处方剂量的靶区体积 / 靶区总体积) × 100%前列腺近距离放疗中的V100目标：V100值临床意义≥ 95%✅ 理想（ABS推荐）90-95%⚠️ 可接受（最低阈值90%）< 90%❌ 不合格，需重新计划示例：靶区体积 = 40 cm³V100 = 95%表示有 38 cm³ 的靶区接受了 ≥ 处方剂量注意：V100需结合其他参数综合评估：D90（90%靶区体积接受的剂量）OAR限制（直肠、膀胱、尿道剂量）剂量均匀性指数 (DHI)来源：AAPM TG-43, ABS Brachytherapy Guidelines...

**Scores:**
- Total: 0.77
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Turn 1](../screenshots/34_MT006_turn1.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

#### Turn 2 ❌

**Input:** And D90?...

**Response:**
> **D90** 是剂量体积直方图（DVH）中的关键参数。**定义：** 照射剂量覆盖**90%靶区体积**时的最低剂量值。```D90 = 使90%的靶区体积接受的剂量 ≥ 此值```**前列腺近距离放疗目标：**| 参数 | 目标 ||------|------|| **D90** | **≥ 处方剂量的 100%** || D90 of 144 Gy | ≥ 144 Gy |**临床...

**Scores:**
- Total: 0.77
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Turn 2](../screenshots/34_MT006_turn2.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

### ❌ MT007

**Multi-turn Test:** 3 turns

#### Turn 1 ✅

**Input:** What is the prostate dose constraint?...

**Response:**
> **前列腺近距离放疗剂量约束：**## 靶区覆盖目标| 参数 | 目标值 | 说明 ||------|--------|------|| **V100** | ≥ 95% | 接受100%处方剂量的靶区体积 || **D90** | ≥ 100% 处方剂量 | 90%靶区体积接受的最低剂量 || **D100** | ≥ 90% 处方剂量 | 靶区最低剂量点 |## OARs 剂量约束（前 列腺癌）| 器官 | 约束 | 参考来源 ||------|------|----------|| **直肠** | D2cc ≤ 72-100 Gy (单药) | QUANTEC, ABS || **直肠** | D0.1cc ≤ 150 Gy | TG-43 || **膀胱** | D2cc ≤ 150 Gy | ABS || **尿道** | D10 ≤ 150 Gy, D30 ≤ 125 Gy | ABS || **阴茎海绵...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 1](../screenshots/34_MT007_turn1.png)

---

#### Turn 2 ❌

**Input:** Now let's talk about cervical cancer. What is the HDR fractionation?...

**Response:**
> 前列腺近距离放疗剂量约束：靶区覆盖目标参数目标值说明V100≥ 95%接受100%处方剂量的靶区体积D90≥ 100% 处方剂量90%靶区体积接受的最低剂量D100≥ 90% 处方剂量靶区最低剂量点OARs 剂量约束（前 列腺癌）器官约束参考来源直肠D2cc ≤ 72-100 Gy (单药)QUANTEC, ABS直肠D0.1cc ≤ 150 GyTG-43膀胱D2cc ≤ 150 GyABS尿道D10 ≤ 150 Gy, D30 ≤ 125 GyABS阴茎海绵体D40 ≤ 50 GyABSI-125 单药治疗 (144 Gy) 具体约束OARD2cc 限值直肠≤ 100-130 Gy膀胱≤ 150 Gy尿道D10 ≤ 150 Gy来源：ABS Guidelines, QUANTEC, AAPM TG-43/64...

**Scores:**
- Total: 0.60
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 0.00

**Screenshot:**
![Turn 2](../screenshots/34_MT007_turn2.png)

**Failure Analysis:**
- Root Cause: language_mismatch
- Description: English input should get English response

---

#### Turn 3 ❌

**Input:** What about the OAR constraints for that?...

**Response:**
> [Historical reference — not current task]**宫颈癌 HDR 近距离放疗分割...

**Scores:**
- Total: 0.55
- Keyword: 0.00
- Completeness: 0.50
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Turn 3](../screenshots/34_MT007_turn3.png)

**Failure Analysis:**
- Root Cause: too_brief
- Description: Response too short (58 chars)

---

